Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer
Following US FDA Approval
Executive Summary
The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.
You may also be interested in...
Finance Watch: Novartis Sets October Separation Date For Sandoz Spin-Off
Novartis revealed detailed terms and a 4 October spin-off date for Sandoz’s standalone debut. Also, MIRA launched a small IPO, but two firms plan to go public in SPAC mergers. Also, Mirati’s $345m offering leads follow-ons offerings and Sangon Biotech raised $290m in venture capital.
Deal Watch: Takeda Calls Upon The UK’s F-star Again For Bispecific Candidates
Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.
Olema Flies Flag For SERDs, Planning Phase III Trials As Rivals Stumble
Several factors differentiate Olema Oncology’s lead drug candidate from the SERD herd, says its CEO Sean Bohen, as the firm looks to partner the ‘ready-for-Phase III multibillion-dollar asset.’